Genome Conferences 2025 | Pharmacogenomics Meetings | Genome Editing Symposiums

Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World’s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 100 Million+ Visitors
  • 75000+ Unique visitors per conference
  • 100000+ Page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Renowned Speakers

Genome conferences, Genetics Experts Meeting, Pharmacogenomics conference 2025 in Philadelphia, Molecular Biology events, Cancer Genomics, Pharmacogenetics, Biochemistry conferences USA, Genome conferences 2025, Genomics and Pharmacogenomics conferences 2025

Henry M Sobell

University of Rochester, USA USA

Genome conferences, Genetics Experts Meeting, Pharmacogenomics conference 2025 in Philadelphia, Molecular Biology events, Cancer Genomics, Pharmacogenetics, Biochemistry conferences USA, Genome conferences 2025, Genomics and Pharmacogenomics conferences 2025

Xiaoliang Sunney Xie

Harvard University, USA USA

Genome conferences, Genetics Experts Meeting, Pharmacogenomics conference 2025 in Philadelphia, Molecular Biology events, Cancer Genomics, Pharmacogenetics, Biochemistry conferences USA, Genome conferences 2025, Genomics and Pharmacogenomics conferences 2025

Ron L. Martin

Nutrigenetics Unlimited, Inc., USA USA

Genome conferences, Genetics Experts Meeting, Pharmacogenomics conference 2025 in Philadelphia, Molecular Biology events, Cancer Genomics, Pharmacogenetics, Biochemistry conferences USA, Genome conferences 2025, Genomics and Pharmacogenomics conferences 2025

Misha Gattengo

Novogene, USA USA

Genome conferences, Genetics Experts Meeting, Pharmacogenomics conference 2025 in Philadelphia, Molecular Biology events, Cancer Genomics, Pharmacogenetics, Biochemistry conferences USA, Genome conferences 2025, Genomics and Pharmacogenomics conferences 2025

Pan Zhang

Coriell Institute, USA USA

Genome conferences, Genetics Experts Meeting, Pharmacogenomics conference 2025 in Philadelphia, Molecular Biology events, Cancer Genomics, Pharmacogenetics, Biochemistry conferences USA, Genome conferences 2025, Genomics and Pharmacogenomics conferences 2025

Sun Yingli

Beijing Institute of Genomics, USA USA

Genome conferences, Genetics Experts Meeting, Pharmacogenomics conference 2025 in Philadelphia, Molecular Biology events, Cancer Genomics, Pharmacogenetics, Biochemistry conferences USA, Genome conferences 2025, Genomics and Pharmacogenomics conferences 2025

Hideko Kaji

Thomas Jefferson University, USA USA

Genome conferences, Genetics Experts Meeting, Pharmacogenomics conference 2025 in Philadelphia, Molecular Biology events, Cancer Genomics, Pharmacogenetics, Biochemistry conferences USA, Genome conferences 2025, Genomics and Pharmacogenomics conferences 2025

Change Tan

University of Missouri,USA USA

Genome 2025

About the Conference

Genome 2025 welcomes every one of the members from everywhere throughout the world to attend the 18th International Conference on Genomics and Pharmacogenomics amid April 03-04, 2025 Madrid, Spain. Which incorporates provoke Keynote introductions, Oral introductions, Poster introductions and Exhibitions. We are regarded to invite all of you to trade and offer your perspectives and experience on Genomics and Pharmacogenomics

Genomics is a region within genetics that concerns the sequencing and examination of a creature’s genome. Genomics additionally includes the investigation of intra-genomic procedures, for example, epistasis, heterosis, and pleiotropy and the interactions between the loci and alleles inside the genome. The fields of molecular biology and genetics are mostly concerned with investigation of role and function of the single genes, a noteworthy subject in today's biomedical research. By difference, genomics does not include single quality research unless the intention is to comprehend a solitary quality's belongings in setting of the whole genome. 

Scope and Importance

The Scope of the conference is to gather all the Doctors, Researchers, Business Delegates and Scientists to approach and deliver all the attendees about the latest scientific advancements on the respective sphere. This Genomics and Pharmacogenomics Conference is the premier event focusing on understanding individual and organizational behavior and decision-making related to genetics, genomics, molecular biology, biotechnology, pharmacy, medicine and academia.

The conference unites assets and expertise to scaffold Genomics and Pharmacogenomics to unveil noteworthy worldwide disclosures in Human Health. It gives an awesome stage to cover recent breakthroughs in Genetics, Pharmacogenomics, Bioinformatics, Plant Genomics, Biotechnology new genomic apparatuses and its partnered territories.

What's New?

The Genomics & Pharmacogenomics has moreover set itself the undertaking of working on numerous levels to set up activities gone for improving collaborations between researchers in fundamental and clinical research and to encourage interdisciplinary research exercises. On an instructive level, the exploration bunch goes for supporting the training and direction of youthful researchers by giving amazing preparing chances to PhD understudies and postdoctoral colleagues. It additionally gives a chief interdisciplinary stage to specialists, professionals and teachers to display and talk about the latest developments, patterns, and worries and in addition useful difficulties experienced and arrangements embraced in the fields of Current Trends in Genomics & Pharmacogenomics

Why to attend?

With members from around the world focused on learning about Genomics & Pharmacogenomics and its advances; this is your best opportunity to reach the largest assemblage of participants from the Genomics & Pharmacogenomics and its allied areas. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Genomics & Pharmacogenomics are hallmarks of this conference.

Target Audience:

  • Genomics and Pharmacogenomics Students
  • Genomics and Pharmacogenomics Researchers
  • Genomics and Pharmacogenomics Faculty
  • Genomics Scientists
  • Genomics Colleges
  • Pharmacology Scientists
  • Pharmacology Health Professionals
  • Genetics Associations and Societies
  • Geneticists
  • Genetic Counselors
  • Bio-pharmacists
  • Business Entrepreneurs
  • Training Institutes
  • Software developing companies
  • Data Management Companies

Sessions and tracks

Track 1: Cancer Genomics

Cancer Genomics is the investigation of innate changes responsible for the malady, using genome sequencing and bioinformatics. Clinical genomics is to upgrade malignant growth treatment and results lie in making sense of which sets of characteristics and quality correspondences impact differing subsets of developments. Worldwide Cancer Genome Consortium (ICGC) is an adamant consistent affiliation that gives a social event to joint exertion among the world's driving infection and genomic experts.

Track 2: Next generation sequencing

Genomics manages structure, capacity, development and mapping of genomes. There are numerous methods in genomics which incorporates Genomic DNA segregation, DNA partition, Cloning and vectors, location of qualities of intrigue, etc. These systems are particularly helpful in the field of drug to analyze irresistible diseases and are additionally utilized in legal sciences, agribusiness.

Track 3: Functional Genomics

Functional Genomics uses a colossal wealth of data conveyed by genomic and transcriptomic assignments to portray quality capacities and cooperation’s. Floats in Functional Genomics are Affymetrix, raised as an early pioneer around thereby making a valuable way to deal with a breakdown quality capacity as a structure. Deft Gen Systems and Febit are making produced miniaturized scale clusters that are conveyed using a littler scale reflect based, shroud less structure.

Track 4: Structural Genomics

Structural Genomics attempts to decide the 3 Dimensional structure of every protein encoded by the genome and used to anticipate novel protein folds dependent on other structural information. It can similarly take the upside of complete genome arrangement so as to choose protein structure. The quality grouping of the objective protein can be contrasted and a known arrangement and data of the structure can be assembled from realized protein structure.

Track 5: Pharmacogenomics

Pharmacogenomics is the investigation of how genes influence a man’s reaction to drugs. This is generally a new field consolidates pharmacology and genomics (the investigation of genes and their capacities) to create successful, safe pharmaceuticals and dosages that will be custom fitted to a man’s hereditary makeup

These genetic differences are utilized to prevent adverse drug reactions and to predict whether a medication will be effective for a specific individual. In the future, Pharmacogenomics will be used for the development of tailored drugs to treat a wide range of health issues such as cardiovascular diseaseAlzheimer diseasecancerHIV/AIDS, and asthma.

Track 6: Clinical genomics

Clinical genomics is the use of genome sequencing to advise quiet analysis and care and it is a rapidly advancing field. Learning of the human genome is far from the completion, be that as it may, there are starting at now utilizes for inherited and genomic information in the middle. Genome sequencing is depended upon to have the best in portraying and diagnosing extraordinary and obtained contaminations, stratifying individuals' tumors to manage treatment (precision sedate), giving information around an individual's threat of making illness or their comprehensible response to treatment (prosperity organization)

The International Standards for Cytogenetics Arrays (ISCA) Consortium, of which OGT is a segment, is a making get-together of sub-atomic intrinsic characteristics labs satisfactorily progressing in the direction of improving human organizations through the foundation of standards for sub-atomic testing, including the age of institutionalized CGH bunches for clinical acquired characteristics investigate. The Cancer Cytogenetics Microarray Consortium (CCMC) is a close get-together, beginning late settled with the objective of developing the focal points given by microarrays to risk explore. These social events keep moving in the direction of sketching out a game-plan of guidelines to guarantee that sub-atomic techniques improve and update the associations given by clinical research labs.

Track 7: Epigenomics and Epigenetics

Epigenomics is the examination of the all-out course of action of epigenetics changes on the innate material of a cell, known as the Epigenomics. Epigenetic changes are reversible modifications on DNA or histones that impact quality articulation without adjusting the DNA succession. Epigenomics upkeep is a reliable method and accepts a basic part in security of eukaryotic genomes by taking an interest in basic natural frameworks like DNA fix. Plant flavones are said to stifle Epigenomics marks that reason malignancies. Two of the most depicted epigenetic changes are DNA methylation and histone alteration.

Epigenetic changes accept a basic part in quality articulation and control, and are incorporated into different cell methods, for instance, in division/progression and tumor genesis.

Track 8: Genetic Disorder

A Genetic Disorder is an inherited issue brought about by at any rate one inconsistencies in the genome, especially a condition that is accessible from birth (intrinsic). Most genetic issue is extremely remarkable and impact one individual in every couple of thousands or millions.

Inherited disarranges may be genetic, passed down from the guardians' characteristics. In other innate issue, deformations may be brought about by new changes or changes to the DNA. In such cases, the defect may be passed down if it occurs in the germ line. A comparative ailment, for instance, a couple of kinds of development, may be brought about by an obtained inherited condition in a couple of individuals, by new changes in different people, and generally by characteristic causes in different people.

Track 9: Comparative Genomics

In the first place, the gigantic amounts of species and the impressively greater size of a couple of genomes make the whole sequencing all things considered, a non-perfect methodology for understanding genome structure. Second, inside a given species the vast majority are hereditarily particular in different ways. What does it truly mean, for example, to "succession a human genome"? The genomes of two individuals who are innately unmistakable vary as for a DNA succession. These two issues and the potential for other novel applications have offered climb to new procedures which, taken together, comprise the field of relative genomics. Farming is the field that gets the prizes of relative genomics. Perceiving the loci of good qualities is a key walk in raising harvests that are upgraded for more noteworthy yield.

Track 10: Animal Genetics

Animal Genetics analyzes the heredity and varieties in animals. Animals have an autonomous legacy of characters because of their generous number of chromosomes. Half breed Analysis is the key technique to think about the legacy of characters and it chooses the possibility of various morphological, physiological and biochemical qualities which a significant part of the time depend just on one of a couple of sets of qualities.

Track 11: Plant Genomics and Molecular Pharming

Molecular Pharming uses plants to make considerable measures of pharmaceutical substances like antibodies and immunizations. It is as same as the system for making Genetically Modified Crops, the counterfeit presentation of qualities into plants. National Science Foundation (NSF) declares its expectation to help plant genome investigate through the Plant Genome Research Program (PGRP). Plant Genomics Research Program (PGRP) grants from the National Science Foundation (NSF) that NSF offers enhancements to help examine coordinated effort with researchers in creating nations. The purpose of Developing Country Collaborations in Plant Genome Research (DCC-PGR) grants is to help collective research connecting U.S. specialists with accomplices from creating nations to take care of issues of common enthusiasm for horticulture, vitality, and the earth while putting US and worldwide analysts at the focal point of a worldwide system of logical brilliance.

Track 12: Gene Editing and Genetic Engineering

Genome Editing infers the methods and systems made as of late for the focused on, specific difference in the hereditary information or genome of living creatures. It addresses an incredibly unique field of research because of the broad assortment of possible applications, the formation of therapeutic proteins, the transfer of steady popular courses of action, cultivating biotechnology and the improvement of new periods of genetically adjusted plants and for the headway of research instruments for example, to examine the limit of a quality.

The CRISPR-cas9 structure makes quality editing in various living creatures and cells like our very own egg, sperm or developing life progressively capable, available and direct than at some other time. These essential capacities have brought forth exchanges incorporating the ethics and employments of the new structure, and have assembled colossal thought far and wide to ensure morally right use.

Track 13: Genomic Instability

Genomic insecurity is a component where a high recurrence of transformation happens inside the genome of Cell heredity. These transformations incorporate changes in DNA and RNA arrangements, chromosomal improvements (aneuploidy). One of the wellsprings of genomic dependability is the high recurrence of remotely caused DNA harm since DNA harms can cause mistaken translation union past the harms or blunders in fix, prompting change. Another wellspring of genome flimsiness might be mutational decreases in articulation of DNA fix qualities. DNA fix is likely a significant wellspring of genome unsteadiness. The system of innate unsteadiness prompts aneuploidy, in which the cells present a chromosome number that, is either higher or lower than the typical supplement for the species.

Track 14: Genomic Medicine

Genomic medicine is portrayed as a rising restorative encourage that incorporates using genomic information around an individual as a noteworthy part of their clinical consideration (e.g., for expository or therapeutic essential initiative) and the prosperity results and system implications of that clinical use. Starting at now, a genomic arrangement is having an impact in the fields of oncology, pharmacology, remarkable and unfamiliar afflictions, and compelling illness.

The NHGRI Genomic Medicine Working Group (GMWG) has been a social event ace accomplices in a movement of genomic arrangement get-togethers to analyze issues enveloping the appointment of a genomic medicate. Besides, the working social occasion provides guidance to the National Advisory Council on Human Genome Research (NACHGR) and NHGRI in various zones of genomic medicine use, for instance, spreading out infrastructural necessities for gathering of genomic arrangement, perceiving related undertakings for future composed endeavors, and investigating progress commonly talking in genomic sedate execution.

Sans cell revolving around DNA is furthermore being examined as a biomarker for tumors. As tumor cells fail miserably they release bits of their changed DNA into the course framework. Sequencing this DNA can give bits of information into the tumor and possible prescriptions, and even be used to screen tumor development (as a differentiating choice to prominent biopsies).

At present, in excess of 100 FDA-embraced medications have pharmacogenomics information in their names, in varying fields, for instance, analgesics, antiviralscardiovascular meds, and unfriendly to development therapeutics.

Track 15: Biomarkers and Microarrays

A biomarker, or regular marker, is a quantifiable pointer of some organic state or condition. A biomarker is a test that can be used to help break down a condition or to help screen a condition or response to treatment. They are used as a piece of various scopes of prescription both in standard restorative practice and besides in research, especially in clinical preliminaries. In medication, a biomarker can be a detectable substance that is brought into an actual existence structure as an approach to examine organ work or various pieces of prosperity. For example, rubidium chloride is used as a radioactive isotope to evaluate perfusion of heart muscle.

Biomarkers continue winding up continuously noteworthy in research and social protection applications, as affirm by the overall market for things required in their ID, endorsement, and use foreseen to accomplish USD 53.34 Billion by 2021 from USD 27.95 Billion of every 2016, creating at a CAGR of 13.8% in the midst of the guess time period (2016–2021).

Miniaturized scale cluster is an apparatus utilized in research center to identify the declarations of thousands of qualities in the meantime. Miniaturized scale cluster innovation has broad application in Pharmacogenomics. Similar investigation of the qualities from an unhealthy and an ordinary cell will recognize the biochemical constitution of the proteins which are combined by the infected qualities. The scientists can utilize this data for incorporating drugs that battle with these proteins and decrease their impact.

DNA small scale cluster innovation helps in the distinguishing proof of new qualities, to become familiar with the ailments like heart ailments, psychological instability, irresistible infection and particularly the investigation of malignant growth.

Track 16: Microbial Genomics

Microorganisms were the important living things on Earth and went before the animals and plants by in excess of 3 billion years. They are the foundation of the biosphere, from both a transformative and a natural perspective. It has been assessed that microbial species incorporate around 60% of the Earth's biomass. The genetic, metabolic and physiological arranged assortment of microbial species is unmistakably more conspicuous than that found in plants and animals. In any case, the ok assortment of the microbial world is, as it were, dark, with shy of what one-bit off 1% of the assessed 2–3 billion microbial species perceived. Of those species that have been depicted, their natural arranged assortment is incredible, having changed in accordance with create under boundaries of temperature, pH, salt concentration and oxygen levels.

Possibly no other region of research has been so strengthened by the utilization of genomic development than the microbial field. It was only five years back that The Institute for Genomic Research (TIGR) circulated the essential completion genome course of action for a free-living structure, Haemophilus influenzae2; since that at first report another 27 microbial genome progressions have been conveyed, with no under 10–20 distinct endeavors at or close climax. These development addresses, overall, one completed genome gathering at customary interims and all signs are that this pace will continue quickening.

Track 17: Nutrigenomics

Nutrigenomics is the investigation of the impacts of sustenance and nourishment constituents on quality articulation, and how hereditary varieties influence the healthful condition. It centers on understanding the communication among supplements and other dietary bio actives with the genome at the atomic dimension, to see how explicit supplements or dietary routines may influence human wellbeing.

Track 18: Personalized and Regenerative Medicine

Personalized Medicine as a novel field of medicine dependent on Pharmacogenetics and Pharmacogenomics data utilized for the remedy of explicit therapeutics strategy for an individual and it likewise covers numerous fields of human services.  Accordingly, Regenerative Medicine and cellular therapy are the new regions of medicine use cell-based items to create personalized medications. iPSCs and individual pluripotent immature microorganisms are the suitable competitors presented for personalized treatments.

Track 19: Bioinformatics and Computational Biology

Bioinformatics is the examination of get-together and dismembering complex natural data, for instance, inherited codes. Nuclear prescription requires the compromise and examination of genomic, sub-nuclear, cell, and furthermore clinical data and it henceforth offers an amazing game plan of challenges to bioinformatics. Bioinformatics nowadays has an essential part both, in translating genomic, transcriptomic, and proteomic data created by high-throughput test headways. The Canadian government is moreover earning substantial sums of money for omics look into, with the Canada Foundation for Innovation backing a few undertakings as a part of a C$30.4 million ($27.6 million) enthusiasm for insightful research. Computational science is the study of utilizing organic information to create relations and calculations among different natural frameworks.

Track 20: Trends in Genomics and Pharmacogenomics

The field of pharmaceutical is altogether changed by new developments; a great deal of this change starts from stimulating advances in genomics. Developments, for instance, liquid biopsies have been made that can distinguish infection DNA even in the underlying stage after its entrance. Masters moreover have discovered five epigenetic marks for harm, and we can foresee that more will come. Today, in case one needs to approach a far reaching approach to manage drug in perspective on genomic appreciation, it suggests putting around $2,000 in one's own specific prosperity.

Around 80% of valuable characteristics in the human genome are conveyed in the brain and in excess of 1,200 remarkable characteristics have been identified with the parthenogenesis of CNS issue and dementia. Pharmacogenetics examinations of psychotropic drug response have focused on choosing the association between assortments specifically confident characteristics and the positive and antagonistic effects of prescription treatment. 10-20% of Western peoples are deficient in characteristics of the CYP superfamily and the pharmacogenomics response of psychotropic meds in like manner depends on upon innate varieties identified with dementia. Up and coming surveys with threatening to dementia drugs or with multifactorial strategies have revealed that the supportive response to standard meds in Alzheimer's disease is genotype-specific.

Market Analysis

Genomics is a discipline which breaks down the capacity and structure of genomes. It utilizes different inspecting, sequencing, and information examination and elucidation systems to interpret, amass, and break down genomes. The learning of finish set of DNA recognizes certain hereditary infections, grow best course of treatment, and add to accuracy prescription.

Pharmacogenomics refers to polygenic drug response phenotypes and encompasses transcriptomics, proteomics, and metabolomics. Mechanisms of pharmacogenetic interactions. Pharmacokinetics involves the absorption, distribution, metabolism, and elimination of pharmaceutics.

The Pharmacogenomics Market size is estimated at USD 8.67 billion in 2024, and is expected to reach USD 11.67 billion by 2029, growing at a CAGR of 6.12% during the forecast period (2024-2029).

The pharmacogenomics market is driven by the rising popularity of precision medicine, coupled with growing research and development expenditures on pharmacogenomics technologies, which is accelerating the development of novel products. The high incidence rate of adverse drug reactions is also driving the higher adoption of pharmacogenomics in the global market.

As per the scope of this report, pharmacogenomics provides accurate insights into making clinical decisions and determining the most effective treatment by varying the dosages of drugs. The field of pharmacogenomics is predicted to treat a wide range of health problems, including cardiovascular diseases, Alzheimer's disease, cancer, HIV/AIDS, and asthma. The pharmacogenomics market is segmented by technology, application, and geography. By technology, the market is segmented into DNA sequencing, microarray, polymerase chain reaction, electrophoresis, mass spectrometry, and other technologies. By application, the market is segmented into drug discovery, neurology, oncology, pain management, and other applications. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. For each segment, the market size is provided in terms of value (USD).

Pharmacogenomics Market, By Offering, 2021 – 2032 (USD Billion)

Pharmacogenomics Market Trends

  • As the global burden of cancer continues to increase, fueled by factors such as aging populations and lifestyle changes, the demand for pharmacogenomics testing and targeted cancer therapies is expected to grow substantially.
  • This trend underscores the importance of pharmacogenomics in addressing the complex challenges posed by cancer and driving advancements in precision oncology.
  • Additionally, the escalating burden of adverse drug reactions underscores the need for pharmacogenomics solutions to mitigate medication risks and enhance patient safety, further driving market growth and innovation.
  • Furthermore, there is a significant increase in research and development investments from pharmaceutical companies, biotechnology firms, and research institutions. This surge in funding is advancing pharmacogenomics technologies and therapies, accelerating the translation of genomic insights into personalized medical   treatments.

Past Conference Report

Genomics 2024

Conference Series LLC Ltd   hosted 17th International Conference on Genomics & Pharmacogenomics during June 15-16, 2024 at London, UK based on the theme “Novel research on Genomics and Pharmacogenomics for Global Health”.

Active participation and generous response was received from the Organizing Committee Members, scientists, researchers, as well as experts from Non-government organizations, and students from diverse groups who made this conference as one of the most successful and productive events in 2017 from Conference Series LLC Ltd .

The conference was marked with several workshops, multiple sessions, Keynote presentations, panel discussions and Poster sessions. We received active participation from scientists, young and brilliant researchers, business delegates and talented student communities representing more than 35 countries, who have driven this event into the path of success.   

The conference was initiated with a warm welcome note by Honorable guests and the Keynote forum. The proceedings went through interactive sessions and panel discussions headed by honorable Moderator Dr. Gregg S. Pettis, Louisiana State University, USA, for the conference.

The conference proceedings were carried out through various Scientific-sessions and plenary lectures, of which the following Speakers were highlighted as Keynote speakers:

The centers of premelton signals the beginning and ends of genes: Henry M. Sobell, University of Rochester, USA

Tamoxifen pharmacogenomics of breast cancer: the controversy and way forward: Hiltrud Brauch, Dr. Margarete Fischer Bosch-Institute of Clinical Pharmacology, Germany

Altered UBIAD1 prenyltransferase function in schnyder corneal dystrophy affects cholesterol metabolism and mitochondrial function: Michael L. Nickerson, National Cancer Institute, USA

Use of Carrier exome screening for prevention of childhood malignancies and other sever congenital abnormalities: Peter L. Nagy, MNG Laboratories, USA

Conference Series LLC Ltd  has taken the privilege of felicitating Genomics-2024 Organizing Committee, Keynote Speakers who supported for the success of this event. Conference Series LLC Ltd  , on behalf of the Organizing Committee congratulates the Best Poster awardees for their outstanding performance in the field of Genomics & Pharmacogenomics and appreciates all the participants who put their efforts in poster presentations and sincerely wishes them success in future endeavours.  

Poster Judging was done by: Dr. Henry M. Sobell, University of Rochester, USA

We are also obliged to various delegate experts, company representatives and other eminent personalities who supported the conference by facilitating active discussion forums. We sincerely thank the Organizing Committee Members for their gracious presence, support, and assistance towards the success of Genomics-2024.

With the unique feedback from the conference, Conference Series LLC Ltd  would like to announce the commencement of the 11th International Conference on Genomics & Pharmacogenomics.

Bookmark your dates: We hope to see you at Genome 2025, Madrid, Spain, during April 03-04, 2025.

To Collaborate Scientific Professionals around the World

Conference Date April 03-04, 2025

Speaker Opportunity

Supported By

Journal of Pharmacogenomics & Pharmacoproteomics Journal of Genetics and Molecular Biology Journal of Clinical & Medical Genomics

All accepted abstracts will be published in respective Conference Series International Journals.

Abstracts will be provided with Digital Object Identifier by


Keytopics

  • Alternative Splicing
  • Cancer Genomics And Tumor Profiling
  • Chromatin Structure And Epigenetics
  • Comparative Genomics
  • DNA Methylation
  • Drug-Metabolizing Enzymes (CYP450 And Others)
  • Ethnic And Racial Differences In Drug Response
  • Functional Annotation Of Genomes
  • Functional Genomics
  • Gene Dosage And Copy Number Variations
  • Gene Editing Techniques (CRISPR-Cas9)
  • Gene Expression Profiling
  • Gene Regulatory Networks
  • Gene-Drug Interactions
  • Genetic Counseling And Ethical Considerations
  • Genetic Epidemiology
  • Genetic Variation And Drug Toxicity
  • Genome-Wide Association Studies (GWAS)
  • Genomic Data Analysis
  • Genomic Imprinting And Parent-of-Origin Effects
  • Genomic Variants (SNPs, INDELs, CNVs)
  • Genomics In Rare Diseases
  • Human Genetic Diversity
  • Human Genome Project
  • Long-read Sequencing Technologies
  • Metagenomics
  • MicroRNAs And Non-coding RNAs
  • Mitochondrial Genomics
  • Next-Generation Sequencing (NGS)
  • Personalized Medicine And Drug Response
  • Pharmacogenomic Biomarkers
  • Pharmacogenomic Guidelines And Regulations
  • Pharmacogenomic Testing In Clinical Practice
  • Pharmacogenomics And Polygenic Risk Scores
  • Pharmacogenomics And Precision Medicine
  • Pharmacogenomics In Infectious Disease Treatment
  • Pharmacogenomics In Oncology
  • Pharmacogenomics In Rare Disease Treatment
  • Pharmacogenomics Of Anticancer Drugs
  • Pharmacogenomics Of Anticoagulants
  • Pharmacogenomics Of Antidepressants
  • Pharmacogenomics Of Cardiovascular Drugs
  • Pharmacogenomics Of Immunosuppressive Drugs
  • Pharmacogenomics Of Pain Management
  • Pharmacokinetics And Pharmacodynamics
  • Population Genomics
  • RNA Sequencing (RNA-Seq)
  • Single-Cell Genomics
  • Somatic Mutations And Cancer Genomics
  • The Role Of Pharmacogenomics In Precision Psychiatry
  • Whole Exome Sequencing (WES)
  • Whole Genome Sequencing (WGS)